Clinical trials: PET/CT
Prostate Cancer
A Phase I Study to Evaluate the Safety and Dosimetry of Imaging With 68Ga-OncoACP3 in Prostate Cancer
The aim of this study is to assess the safety and dosimetry of imaging with [68Ga]Ga-OncoACP3 in patients with prostate cancer.
- Trial name
- SWAP (NCT07600554)
- Testing
- [68Ga]Ga-OncoACP3
- Where
- 2 sites in Italy
- Volunteers
- 20 people
- Sponsor
- Philogen S.p.A.
High Risk Prostate Carcinoma
Evaluate the Clinical Usefulness of [F-18]Florastamin PET/CT Imaging Diagnosis Compared to MRI Diagnosis
Only in subjects who satisfy the inclusion/exclusion criteria, a single dose of [F-18]Florastamin at 10 ± 1 mCi is IV administered at Visit 2, and [F-18]Florastamin PET/CT images are obtained from the head to thigh after 110 ± 10…
- Trial name
- NCT05004285
- Testing
- [F-18]Florastamin
- Where
- 5 sites in South Korea
- Volunteers
- 398 people
- Sponsor
- FutureChem
Graft Versus Host Disease
Detection of Graft Versus Host Disease With [18F]F-AraG
This is a single-center imaging study to determine utility of in vivo imaging with [18F]F-AraG to identify sites of Graft Versus Host Disease (GVHD) in patients highly suspected of having acute GVHD who require systemic therapy…
- Trial name
- NCT03367962
- Testing
- [18F]F-Ara-G
- Where
- United States
- Volunteers
- 9 people, healthy volunteers welcome
- Sponsor
- CellSight Technologies, Inc.
Metastatic Breast Cancer
Clinical Utility of FES F18 PET/CT in Metastatic Breast Cancer Patients
This is a phase 4, multi-center, open-label, prospective cohort study to evaluate the clinical utility of Fluoroestradiol F18 (Cerianna) PET/CT to guide therapeutic management in ER-positive, HER2-negative metastatic breast…
- Trial name
- NCT05068726
- Testing
- 18F Fluoroestradiol Radiopharmaceutical with PET/CT
- Where
- 24 sites in United States
- Volunteers
- 51 people
- Sponsor
- GE Healthcare
Atherosclerosis, Inflammatory Activity in Carotid Arteries
Effects of Crestor on Inflammation of Atherosclerotic Plaques
The primary aim of this study is to investigate the effect of 40 mg dose of rosuvastatin on carotid plaque inflammation measured with MRI and PET scanning, to evaluate whether these techniques are promising for future proof of…
- Trial name
- NCT00689416
- Testing
- rosuvastatin
- Where
- Sweden
- Volunteers
- 74 people, healthy volunteers welcome
- Sponsor
- AstraZeneca
Marginal Zone Lymphoma
[68Ga]Ga-PentixaFor-PET Imaging for Staging of Marginal Zone Lymphoma
This will be a pivotal prospective prospective, international, multi-center, comparative, randomized, cross-over, open-label lymphoma diagnostic trial to assess the diagnostic performance and safety of the positron emission…
- Trial name
- LYMFOR (NCT06125028)
- Testing
- [68Ga]Ga-PentixaFor, [18F]Fluorodeoxyglucose
- Where
- 12 sites in Austria, France and 3 more
- Volunteers
- 8 people
- Sponsor
- Pentixapharm AG
Neuroendocrine Tumors
Copper Cu 64 Dotatate for the Detection, Localization and Monitoring of SSTR Expressing (NETs)
This is an open-label, multi-center expanded access program designed to provide access to Copper Cu 64 Dotatate for the detection, localization, and monitoring of NETs to patients that did not have access during the Phase 3 Trial.
- Trial name
- NCT04334837
- Testing
- Copper Cu 64 Dotatate
- Sponsor
- Curium US LLC
Clear Cell Renal Cell Carcinoma (ccRCC)
Evaluation of Safety, Pharmacokinetics, Distribution，Radiation Safety and Sensitivity/Specificity of PET/CT Imaging With 68Ga-NYM096 in Participants With IRM
68Ga-NYM096 is a carbonic anhydrase IX (CAIX)-targeted imaging agent that is under clinical development as a non-invasive diagnostic imaging agent for the detection of clear cell renal cell carcinoma (ccRCC).
- Trial name
- NCT07768306
- Testing
- 68Ga-NYM096 injection
- Volunteers
- 20 people
- Sponsor
- Norroy Bioscience Co., LTD
Prostate Cancer
Study of 18F-Florastamin PET/CT Imaging in Patients With at Least Intermediate Risk Prostate Cancer
In this study, 18F-Florastamin PET/CT will be performed in patients with at least intermediate risk prostate cancer, to assess the diagnostic performance and safety of 18F-Florastamin PET/CT imaging.
- Trial name
- NCT06011304
- Testing
- [18F]Florastamin Injection
- Where
- China
- Volunteers
- 287 people
- Sponsor
- HTA Co., Ltd.
Prosthetic Joint Infections
[124I]FIAU PET-CT Scanning in Patients With Pain in a Prosthetic Knee or Hip Joint
This protocol will evaluate the sensitivity and specificity of [124I]FIAU as a diagnostic imaging agent for the detection of prosthetic joint infections in patients.
- Trial name
- PJI (NCT01705496)
- Testing
- [124I]FIAU
- Where
- 10 sites in United States
- Volunteers
- 23 people
- Sponsor
- BioMed Valley Discoveries, Inc
Prostate Cancer, Prostate Cancer Recurrent
Efficacy of [18F]PSMA-1007 PET/CT in Patients With Biochemial Recurrent Prostate Cancer
This study evaluates the diagnostic performance and safety of [18F]PSMA-1007 PET/CT imaging in patients with suspected recurrence of prostate cancer after previous definitive treatment.
- Trial name
- NCT04742361
- Testing
- [18F]PSMA-1007
- Where
- 6 sites in United States, Netherlands and 1 more
- Volunteers
- 136 people
- Sponsor
- ABX advanced biochemical compounds GmbH
Prostate Cancer
18F Fluciclovine (FACBC) PET/CT in Patients With Rising PSA After Initial Prostate Cancer Treatment
This prospective study will enroll up to 330 men with PSA-persistent or PSA-recurrent prostate cancer after curative-intent primary therapy and negative or equivocal findings on standard-of-care imaging.
- Trial name
- LOCATE (NCT02680041)
- Testing
- 18F-fluciclovine PET CT
- Where
- 17 sites in United States
- Volunteers
- 221 people
- Sponsor
- Blue Earth Diagnostics
Clear Cell Renal Cell Carcinoma
89Zr-TLX250 for PET/CT Imaging of ccRCC- ZIRCON Study
89Zr-TLX250 is under clinical development as a diagnostic agent targeting clear cell renal cell carcinoma.
- Trial name
- 89ZR-TLX250 (NCT03849118)
- Testing
- 89Zr-girentuximab
- Where
- 31 sites in United States, Australia and 6 more
- Volunteers
- 300 people
- Sponsor
- Telix Pharmaceuticals (Innovations) Pty Limited
Prostate Cancer
A Phase 1 Pilot Study of 99mTc-MIP-1404 SPECT/CT Imaging to Histology in Men With Prostate Cancer
This is a single arm, open label study of up to 24 prostate cancer patients scheduled for prostatectomy and/or pelvic lymph node dissection.
- Trial name
- NCT01615406
- Testing
- 99mTc MIP 1404
- Where
- United States
- Volunteers
- 9 people
- Sponsor
- Molecular Insight Pharmaceuticals, Inc.
Prostate Cancer
PET/CT Imaging Study of the Safety and Diagnostic Performance of [68Ga]RM2 in Patients With Primary Prostate Cancer
The aim of this study is to investigate safety and diagnostic performance of the 68Ga labeled PET tracer [68Ga]RM2 for detection and localization of primary prostate cancer confirmed by histopathology of the prostate as a…
- Trial name
- NCT02483884
- Testing
- [68Ga]RM2, PET/CT
- Where
- 2 sites in Austria, Finland
- Volunteers
- 30 people
- Sponsor
- Lantheus Biosciences Ltd.
Prostate Cancer
Diagnostic Performance of [18F]PSMA-1007 PET/CT Imaging in Patients With Newly-Diagnosed Prostate Cancer
This study assess the Diagnostic Performance of [18F]PSMA-1007 PET/CT Imaging in Patients with Newly-Diagnosed High-Risk or Very-High-Risk Prostate Cancer
- Trial name
- NCT06122584
- Testing
- [18F]PSMA-1007
- Where
- 18 sites in France, Germany and 4 more
- Volunteers
- 380 people
- Sponsor
- ABX advanced biochemical compounds GmbH
Oncology
Demonstration Of A Next Generation PET CT System
The intent of this evaluation is to obtain user feedback on device performance, user preference, image quality, workflow, and new device features, a necessary part of product development.
- Trial name
- NCT05122715
- Testing
- Additional PET/CT Scan
- Where
- Israel
- Volunteers
- 70 people
- Sponsor
- GE Healthcare
Healthy Volunteers, Cancer Patients
Clinical Study of 68Ga-LNC1007 Injection PET/CT
This study is a single-arm, single-center trial aimed at evaluating the safety, pharmacokinetics, biodistribution and dosimetry of 68Ga-LNC1007 Injection in adult healthy volunteers and solid tumor patients.
- Trial name
- NCT06463782
- Testing
- 68Ga-LNC1007 Injection
- Where
- Singapore
- Volunteers
- 8 people, healthy volunteers welcome
- Sponsor
- Yantai LNC Biotechnology Singapore PTE. LTD.
Prostate Cancer
Study of 18F-DCFPyL PET/CT Imaging in Patients With Prostate Cancer
This study evaluates the safety and diagnostic performance of 18F-DCFPyL Injection in patients with at least high risk prostate cancer who are planned for radical prostatectomy with lymphadenectomy (Cohort A) or in patients with…
- Trial name
- OSPREY (NCT02981368)
- Testing
- 18F-DCFPyL Injection, PET/CT imaging
- Where
- 10 sites in United States, Canada
- Volunteers
- 385 people
- Sponsor
- Progenics Pharmaceuticals, Inc.